Cufence (trientine dihydrochloride)
- Region
- 🇪🇺 EU
- Active substance
- trientine dihydrochloride
- Company
- Univar Solutions BV
- Status
- Authorised
- Therapeutic area
- Hepatolenticular Degeneration
- CHMP opinion
- Wed 29 May 2019
- EU approval
- Thu 25 Jul 2019
- Application
- EMEA/H/C/004111
- ATC
- A16A
- Official record
- www.ema.europa.eu
Indication
Cufence is indicated for the treatment of Wilson’s disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older.
Regulatory milestones
No milestones recorded in the last year.
Follow Cufence
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.